FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 05/2025”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of May 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 15,796m (-9% vs. 2024)
- Biotech/Pharma received 40% of the total investment volume (EUR 6,357m) with oncology being the leading indication (27%)
- In May Neuralink secured the highest transaction volume with EUR 576m, followed by Pathos with EUR 327m and Lumicell with EUR 176m
- Illumina (United States) is the most active investor (by deal volume in 2025), followed by Regeneron Pharmaceuticals (United States) and Bain Capital Life Sciences (United States)
To access the full report, please click here.